<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SERTRALINE HYDROCHLORIDE - sertraline hydrochloride tablet, film coated </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<h1>Sertraline Hydrochloride Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_9bb26bb2-6269-56e8-e9d9-9d5035f7ea25"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Suicidality and Antidepressant Drugs</span></p>
<p><span class="Bold">Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Anyone considering the use of Sertraline Hydrochloride Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and certain other psychiatric disorders are themselves associated with increases in the risk of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.  Families and caregivers should be advised of the need for close observation and communication with the prescriber.  Sertraline Hydrochloride Tablets are not approved for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in pediatric patients. (See </span><span class="Bold"><a href="#LINK_cdf73175-d627-8046-9062-cbf9b6840603">Warnings: Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></span><span class="Bold">, </span><span class="Bold"><a href="#LINK_028ac8bd-3815-2b83-6784-3370ea156d48">Precautions: Information for Patients</a></span><span class="Bold">, and </span><span class="Bold"><a href="#LINK_939d50b1-c90c-d113-98b2-167fbee20dba">Precautions: Pediatric Use</a></span><span class="Bold">)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_86cfb60a-7b40-0d25-ae42-d285223ac188"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Sertraline is a selective serotonin reuptake inhibitor (SSRI) for oral administration. It has a molecular weight of 342.7. Sertraline hydrochloride has the following chemical name: (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine hydrochloride.<br>The empirical formula C<span class="Sub">17</span>H<span class="Sub">17</span>NC<span class="Sub">l2</span>∙HCl is represented by the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=250d998f-7100-495c-81ff-10fcfd5ba61d&amp;name=sertraline-hydrochloride-tablets-1.jpg"></div>
<p>Sertraline hydrochloride is a white crystalline powder that is slightly soluble in water and isopropyl alcohol, and sparingly soluble in ethanol. </p>
<p>Sertraline is supplied for oral administration as scored tablets containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline and the following inactive ingredients: D &amp; C Yellow #10 aluminum lake (in 25 mg tablet), FD &amp; C Blue #2 aluminum lake (in 25 mg &amp; 50 mg tablets), magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone K30, sodium starch glycolate, talc, titanium dioxide &amp; yellow iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_d9cd2345-271b-15b0-de40-0c30c1db0782"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_d906f17a-1acc-352e-15d1-b494d9251c34"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">The mechanism of action of sertraline is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin (5HT). Studies at clinically relevant doses in man have demonstrated that sertraline blocks the uptake of serotonin into human platelets. <span class="Italics">In vitro</span> studies in animals also suggest that sertraline is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. <span class="Italics">In vitro</span> studies have shown that sertraline has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of sertraline was found in animals to down regulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. Sertraline does not inhibit monoamine oxidase.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_ab8959f3-622c-a71b-6d28-1039b3a05d6d"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_087bf188-72f7-4f4e-87c4-f9da2785682e"></a><a name="section-2.3"></a><p></p>
<h2>Systemic Bioavailability</h2>
<p class="First">In man, following oral once-daily dosing over the range of 50 to 200 mg for 14 days, mean peak plasma concentrations (C<span class="Sub">max</span>) of sertraline occurred between 4.5 to 8.4 hours post-dosing. The average terminal elimination half-life of plasma sertraline is about 26 hours. Based on this pharmacokinetic parameter, steady-state sertraline plasma levels should be achieved after approximately one week of once-daily dosing. Linear dose-proportional pharmacokinetics were demonstrated in a single dose study in which the C<span class="Sub">max </span>and area under the plasma concentration time curve (AUC) of sertraline were proportional to dose over a range of 50 to 200 mg. Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation, compared to a single dose, of sertraline with repeated dosing over a 50 to 200 mg dose range. The single dose bioavailability of sertraline tablets is approximately equal to an equivalent dose of solution. </p>
<p>The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the C<span class="Sub">max </span>was 25% greater, while the time to reach peak plasma concentration (T<span class="Sub">max</span>) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, T<span class="Sub">max</span> was slightly prolonged from 5.9 hours to 7.0 hours with food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7826d2a7-73e9-54f2-1b46-912440b9717c"></a><a name="section-2.4"></a><p></p>
<h2>Metabolism</h2>
<p class="First">Sertraline undergoes extensive first pass metabolism. The principal initial pathway of metabolism for sertraline is N-demethylation. </p>
<p>N-desmethylsertraline has a plasma terminal elimination half-life of 62 to 104 hours. Both<span class="Italics"> in vitro</span> biochemical and <span class="Italics">in vivo</span> pharmacological testing have shown N-desmethylsertraline to be substantially less active than sertraline. Both sertraline and N-desmethylsertraline undergo oxidative deamination and subsequent reduction, hydroxylation, and glucuronide conjugation. In a study of radiolabeled sertraline involving two healthy male subjects, sertraline accounted for less than 5% of the plasma radioactivity. About 40-45% of the administered radioactivity was recovered in urine in 9 days. Unchanged sertraline was not detectable in the urine. For the same period, about 40-45% of the administered radioactivity was accounted for in feces, including 12-14% unchanged sertraline. </p>
<p>Desmethylsertraline exhibits time-related, dose dependent increases in AUC (0-24 hour), C<span class="Sub">max</span> and C<span class="Sub">min</span>, with about a 5-9 fold increase in these pharmacokinetic parameters between day 1 and day 14.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b0b33804-82d9-6c0c-65d3-9ffcb7715113"></a><a name="section-2.5"></a><p></p>
<h2>Protein Binding</h2>
<p class="First"><span class="Italics">In vitro</span> protein binding studies performed with radiolabeled <span class="Sup">3</span>H-sertraline showed that sertraline is highly bound to serum proteins (98%) in the range of 20 to 500 ng/mL. However, at up to 300 and 200 ng/mL concentrations, respectively, sertraline and N-desmethylsertraline did not alter the plasma protein binding of two other highly protein bound drugs, viz., warfarin and propranolol (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5b01ccb5-2f36-e855-2b94-640fb25330ce"></a><a name="section-2.6"></a><p></p>
<h2>Pediatric Pharmacokinetics</h2>
<p class="First">Sertraline pharmacokinetics were evaluated in a group of 61 pediatric patients (29 aged 6 to12 years, 32 aged 13 to 17 years). Patients included both males (N=28) and females (N=33). During 42 days of chronic sertraline dosing, sertraline was titrated up to 200 mg/day and maintained at that dose for a minimum of 11 days. On the final day of sertraline 200 mg/day, the 6-12 year old group exhibited a mean sertraline AUC (0-24 hr) of 3107 ng-hr/mL, mean C<span class="Sub">max </span>of 165 ng/mL, and mean half-life of 26.2 hr. The 13-17 year old group exhibited a mean sertraline AUC (0-24 hr) of 2296 ng-hr/mL, mean C<span class="Sub">max</span> of 123 ng/mL, and mean half-life of 27.8 hr. Higher plasma levels in the 6-12 year old group were largely attributable to patients with lower body weights. No gender associated differences were observed. By comparison, a group of 22 separately studied adults between 18 and 45 years of age (11 male, 11 female) received 30 days of 200 mg/day sertraline and exhibited a mean sertraline AUC (0-24 hr) of 2570 ng-hr/mL, mean C<span class="Sub">max</span> of 142 ng/mL, and mean half-life of 27.2 hr. Relative to the adults, both the 6-12 year olds and the 13-17 year olds showed about 22% lower AUC (0-24 hr) and C<span class="Sub">max</span> values when plasma concentration was adjusted for weight. These data suggest that pediatric patients metabolize sertraline with slightly greater efficiency than adults. Nevertheless, lower doses may be advisable for pediatric patients given their lower body weights, especially in very young patients, in order to avoid excessive plasma levels (see <a href="#LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bffa737b-c926-a57c-4d65-3d692cf0ea31"></a><a name="section-2.7"></a><p></p>
<h2>Age</h2>
<p class="First">Sertraline plasma clearance in a group of 16 (8 male, 8 female) elderly patients treated for 14 days at a dose of 100 mg/day was approximately 40% lower than in a similarly studied group of younger (25 to 32 y.o.) individuals. Steady-state, therefore, should be achieved after 2 to 3 weeks in older patients. The same study showed a decreased clearance of desmethylsertraline in older males, but not in older females. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_319402ff-3a1e-9c65-c79d-9c5f1077e84a"></a><a name="section-2.8"></a><p></p>
<h2>Liver Disease</h2>
<p class="First">As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of sertraline. In patients with chronic mild liver impairment (N=10, 8 patients with Child-Pugh scores of 5-6 and 2 patients with Child-Pugh scores of 7-8) who received 50 mg sertraline per day maintained for 21 days, sertraline clearance was reduced, resulting in approximately 3-fold greater exposure compared to age-matched volunteers with no <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (N=10).  The exposure to desmethylsertraline was approximately 2-fold greater compared to age-matched volunteers with no <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  There were no significant differences in plasma protein binding observed between the two groups.  The effects of sertraline in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied.  The results suggest that the use of sertraline in patients with liver disease must be approached with caution. If sertraline is administered to patients with liver impairment, a lower or less frequent dose should be used (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a> and <a href="#LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f41e0e94-108c-67ee-ba3c-72a0ba303fa4"></a><a name="section-2.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">Sertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination. In volunteers with mild to moderate (CLcr =30-60 mL/min), moderate to severe (CLcr =10-29 mL/min) or severe (receiving hemodialysis) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (N=10 each group), the pharmacokinetics and protein binding of 200 mg sertraline per day maintained for 21 days were not altered compared to age-matched volunteers (N=12) with no <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Thus sertraline multiple dose pharmacokinetics appear to be unaffected by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_5fce1524-65a4-3b54-1903-adb6dc8f7736"></a><a name="section-2.10"></a><p></p>
<h2>Clinical Trials</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a91d0a18-edad-cffd-080a-dca5620ec1eb"></a><a name="section-2.11"></a><p></p>
<h2>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First">The efficacy of sertraline as a treatment for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> was established in two placebo-controlled studies in adult outpatients meeting DSM-III criteria for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. Study 1 was an 8-week study with flexible dosing of sertraline in a range of 50 to 200 mg/day; the mean dose for completers was 145 mg/day. Study 2 was a 6-week fixed-dose study, including sertraline doses of 50, 100, and 200 mg/day. Overall, these studies demonstrated sertraline to be superior to placebo on the Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale and the Clinical Global Impression Severity and Improvement scales. Study 2 was not readily interpretable regarding a dose response relationship for effectiveness.</p>
<p>Study 3 involved depressed outpatients who had responded by the end of an initial 8-week open treatment phase on sertraline 50-200 mg/day. These patients (N=295) were randomized to continuation for 44 weeks on double-blind sertraline 50-200 mg/day or placebo. A statistically significantly lower relapse rate was observed for patients taking sertraline compared to those on placebo. The mean dose for completers was 70 mg/day. Analyses for gender effects on outcome did not suggest any differential responsiveness on the basis of sex. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_af7dea93-7785-7716-8429-a4dad483622e"></a><a name="section-2.12"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">Premenstrual Dysphoric Disorder</span> (PMDD)</h2>
<p class="First">The effectiveness of sertraline for the treatment of PMDD was established in two double-blind, parallel group, placebo-controlled flexible dose trials (Studies 1 and 2) conducted over 3 menstrual cycles.  Patients in Study 1 met DSM-III-R criteria for Late Luteal Phase Dysphoric Disorder (LLPDD), the clinical entity now referred to as <span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">Premenstrual Dysphoric Disorder</span> (PMDD) in DSM-IV.  Patients in Study 2 met DSM-IV criteria for PMDD. Study 1 utilized daily dosing throughout the study, while Study 2 utilized luteal phase dosing for the 2 weeks prior to the onset of menses.  The mean duration of PMDD symptoms for these patients was approximately 10.5 years in both studies.  Patients on oral contraceptives were excluded from these trials; therefore, the efficacy of sertraline in combination with oral contraceptives for the treatment of PMDD is unknown.</p>
<p>Efficacy was assessed with the Daily Record of Severity of Problems (DRSP), a patient-rated instrument that mirrors the diagnostic criteria for PMDD as identified in the DSM-IV, and includes assessments for mood, physical symptoms, and other symptoms. Other efficacy assessments included the Hamilton <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> Rating Scale (HAMD-17), and the Clinical Global Impression Severity of Illness (CGI-S) and Improvement (CGI-I) scores.</p>
<p>In Study 1, involving n=251 randomized patients, sertraline treatment was initiated at 50 mg/day and administered daily throughout the menstrual cycle.  In subsequent cycles, patients were dosed in the range of 50-150 mg/day on the basis of clinical response and toleration.  The mean dose for completers was 102 mg/day.  Sertraline administered daily throughout the menstrual cycle was significantly more effective than placebo on change from baseline to endpoint on the DRSP total score, the HAMD-17 total score, and the CGI-S score, as well as the CGI-I score at endpoint. </p>
<p>In Study 2, involving n=281 randomized patients, sertraline treatment was initiated at 50 mg/day in the late luteal phase (last 2 weeks) of each menstrual cycle and then discontinued at the onset of menses.  In subsequent cycles, patients were dosed in the range of 50-100 mg/day in the luteal phase of each cycle, on the basis of clinical response and toleration. Patients who were titrated to 100 mg/day received 50 mg/day for the first 3 days of the cycle, then 100 mg/day for the remainder of the cycle.  The mean sertraline dose for completers was 74 mg/day. Sertraline administered in the late luteal phase of the menstrual cycle was significantly more effective than placebo on change from baseline to endpoint on the DRSP total score and the CGI-S score, as well as the CGI-I score at endpoint. </p>
<p>There was insufficient information to determine the effect of race or age on outcome in these studies. </p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_7538a494-61ef-f8c0-dded-873ff509c897"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5fef33fc-c807-d075-199f-1437d1d790e3"></a><a name="section-3.1"></a><p></p>
<h2>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First">Sertraline is indicated for the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in adults. </p>
<p>The efficacy of sertraline hydrochloride in the treatment of a major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (see <a href="#LINK_5fce1524-65a4-3b54-1903-adb6dc8f7736">Clinical Trials under CLINICAL PHARMACOLOGY</a>). </p>
<p>A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">psychomotor agitation</span> or retardation, loss of interest in usual activities or decrease in sexual drive, increased <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, feelings of guilt or worthlessness, <span class="product-label-link" type="condition" conceptid="4111210" conceptname="Bradyphrenia">slowed thinking</span> or impaired concentration, and a <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>. </p>
<p>The antidepressant action of sertraline hydrochloride in hospitalized depressed patients has not been adequately studied. </p>
<p>The efficacy of sertraline hydrochloride in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline for extended periods should be reevaluated periodically  (see <a href="#LINK_5fce1524-65a4-3b54-1903-adb6dc8f7736">Clinical Trials under CLINICAL PHARMACOLOGY</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_554cca46-6312-41e6-a9b8-ddf63d3eec99"></a><a name="section-3.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">Premenstrual Dysphoric Disorder</span> (PMDD)</h2>
<p class="First">Sertraline is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">premenstrual dysphoric disorder</span> (PMDD) in adults. </p>
<p>The efficacy of sertraline in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III­-R/IV category of PMDD (see <a href="#LINK_5fce1524-65a4-3b54-1903-adb6dc8f7736">Clinical Trials under CLINICAL PHARMACOLOGY</a>). </p>
<p>The essential features of PMDD include markedly <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>, affective lability, and persistent <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span> or <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control.  Physical symptoms associated with PMDD include <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, joint and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. </p>
<p>The effectiveness of sertraline in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials.  Therefore, the physician who elects to use sertraline for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see <a href="#LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_a85ba30a-ba76-4070-d76f-c5209dc256d8"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Concomitant use in patients taking monoamine oxidase inhibitors (MAOIs) is contraindicated (see <a href="#LINK_7bbfca91-65da-50bd-aeb2-941879634f98">WARNINGS</a>). Concomitant use in patients taking pimozide is contraindicated (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a>).<br>Sertraline hydrochloride is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sertraline or any of the inactive ingredients in sertraline hydrochloride tablets.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_7bbfca91-65da-50bd-aeb2-941879634f98"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_cdf73175-d627-8046-9062-cbf9b6840603"></a><a name="section-5.1"></a><p></p>
<h2>Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD), both adult and pediatric, may experience worsening of their <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.</p>
<p><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> is a known risk of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.  There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. </p>
<p>The pooled analyses of placebo-controlled trials in children and adolescents with MDD, <span class="product-label-link" type="condition" conceptid="440374" conceptname="Obsessive-compulsive disorder">obsessive compulsive disorder</span> (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications. The risk differences (drug-placebo differences in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.</p>
<table>
<caption><span>Table 1</span></caption>
<col>
<col>
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="top">Age Range</th>
<th class="Lrule Rrule" align="center" valign="top">Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center" valign="top"> </td>
<td class="Lrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"> </td>
<td class="Lrule Rrule" align="center" valign="top"> Increases Compared to Placebo</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"> &lt;18</td>
<td class="Lrule Rrule" align="center" valign="top"> 14 additional cases</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"> 18–24</td>
<td class="Lrule Rrule" align="center" valign="top"> 5 additional cases</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"> </td>
<td class="Lrule Rrule" align="center" valign="top"> </td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"> </td>
<td class="Lrule Rrule" align="center" valign="top"> Decreases Compared to Placebo</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"> 25–64</td>
<td class="Lrule Rrule" align="center" valign="top"> 1 fewer case</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top"> ≥65</td>
<td class="Lrule Rrule" align="center" valign="top"> 6 fewer cases</td>
</tr>
</tbody>
</table>
<p>No <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> occurred in any of the pediatric trials. There were <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> that the use of antidepressants can delay the recurrence of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p><span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.  </span></p>
<p>The following symptoms, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, have been reported in adult and pediatric patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> as well as for other indications, both psychiatric and nonpsychiatric.  Although a causal link between the emergence of such symptoms and either the worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. </p>
<p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a> and <a href="#LINK_b35957f5-25e8-066d-4809-69b518049085">DOSAGE AND ADMINISTRATION—Discontinuation of Treatment</a> with Sertraline Hydrochloride Tablets, for a description of the risks of discontinuation of Sertraline Hydrochloride Tablets).</p>
<p><span class="Bold">Families and caregivers of patients being treated with antidepressants for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> or other indications, both psychiatric and nonpsychiatric</span>,<span class="Bold"> should be alerted about the need to monitor patients for the emergence of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. </span>Prescriptions for sertraline hydrochloride should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_809ed5a2-bf29-0aad-fea8-a88765507392"></a><a name="section-5.2"></a><p></p>
<h2>Screening Patients for Bipolar Disorder</h2>
<p class="First">A major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive episode</span> may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">depressive symptoms</span> should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, bipolar disorder, and  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. It should be noted that Sertraline Hydrochloride is not approved for use in treating <span class="product-label-link" type="condition" conceptid="436665" conceptname="Bipolar disorder">bipolar depression</span>.</p>
<p><span class="Bold">Cases of serious sometimes fatal reactions have been reported in patients receiving sertraline hydrochloride, a selective serotonin reuptake inhibitor (SSRI), in combination with a monoamine oxidase inhibitor (MAOI). Symptoms of a drug interaction between an SSRI and an MAOI include: <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuations of vital signs, <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> that include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and extreme <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> progressing to <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. These reactions have also been reported in patients who have recently discontinued an SSRI and have been started on an MAOI. Some cases presented with features resembling <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Therefore, sertraline</span><span class="Bold">should not be used in combination with an MAOI, or within 14 days of discontinuing treatment with an MAOI. Similarly, at least 14 days should be allowed after stopping sertraline</span><span class="Bold">before starting an MAOI.</span></p>
<p><span class="Bold">The concomitant use of sertraline hydrochloride with MAOIs intended to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is contraindicated </span>(see <a href="#LINK_a85ba30a-ba76-4070-d76f-c5209dc256d8">CONTRAINDICATIONS</a> and <a href="#LINK_7bbfca91-65da-50bd-aeb2-941879634f98">WARNINGS – Potential for Interaction with Monoamine Oxidase Inhibitors</a> ).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_29628d2b-27c5-4527-ec38-23e7d0e08d09"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)- like Reactions:</h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including sertraline hydrochloride treatment, but particularly with concomitant use of serotonergic drugs (including triptans) and with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>, in its most severe form can resemble <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, which includes <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> with possible rapid fluctuation of vital signs, and <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. Patients should be monitored for the emergence of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> or NMS-like signs and symptoms.</p>
<p>The concomitant use of sertraline hydrochloride with MAOIs intended to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> is contraindicated.</p>
<p>If concomitant treatment of SNRIs and SSRIs, including sertraline hydrochloride, with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p>
<p>The concomitant use of SNRIs and SSRIs, including serteraline hydrochloride, with serotonin precursors (such as tryptophan) is not recommended.</p>
<p>Treatment with sertraline hydrochloride and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_fb937ef3-824c-bfbe-deff-28c39573f395"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_07f92f93-32c2-8d3a-8407-00f269507d36"></a><a name="section-6.2"></a><p></p>
<h2>Activation of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span>/<span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">Hypomania</span></h2>
<p class="First">During premarketing testing, <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span> or <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> occurred in approximately 0.4% of sertraline hydrochloride treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_89ebd2a8-c4d6-147f-b755-f09882ac3f4a"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></h2>
<p class="First">Significant <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> may be an undesirable result of treatment with sertraline for some patients, but on average, patients in controlled trials had minimal, 1 to 2 pound <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, versus smaller changes on placebo. Only rarely have sertraline patients been discontinued for <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_028abc0f-9464-fb59-552e-1951725c0eb4"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span></h2>
<p class="First">Sertraline hydrochloride has not been evaluated in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder. These patients were excluded from clinical studies during the product’s premarket testing. No <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were observed among approximately 3000 patients treated with sertraline hydrochloride in the development program for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. However, 4 patients out of approximately 1800 (220 &lt;18 years of age) exposed during the development program for another disorder experienced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, representing a crude incidence of 0.2%. Three of these patients were adolescents, two with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder and one with a family history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, none of whom were receiving anticonvulsant medication. Accordingly, sertraline should be introduced with care in patients with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7cb50c31-ea67-64b9-9feb-99f781c9a811"></a><a name="section-6.5"></a><p></p>
<h2>Discontinuation of Treatment with Sertraline</h2>
<p class="First">During marketing of Sertraline hydrochloride and other SSRIs and SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> (e.g. <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">electric shock sensations</span>), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. </p>
<p>Patients should be monitored for these symptoms when discontinuing treatment with Sertraline hydrochloride. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see <a href="#LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_24fb2ab3-6389-4111-5c26-b3ed8fc81a80"></a><a name="section-6.6"></a><p></p>
<h2>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">SSRIs and SNRIs, including sertraline hydrochloride, may increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events related to SSRIs and SNRIs use have ranged from <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> to life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>. </p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concomitant use of sertraline hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_160723b6-fedb-9869-b086-1c134faddd6b"></a><a name="section-6.7"></a><p></p>
<h2>Weak Uricosuric Effect</h2>
<p class="First">Sertraline Hydrochloride is associated with a mean decrease in serum uric acid of approximately 7%. The clinical significance of this weak uricosuric effect is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6a28ca28-e68a-96f1-6f50-39f465312221"></a><a name="section-6.8"></a><p></p>
<h2>Use in Patients with Concomitant Illness</h2>
<p class="First">Clinical experience with sertraline hydrochloride in patients with certain concomitant systemic illness is limited. Caution is advisable in using sertraline in patients with diseases or conditions that could affect metabolism or hemodynamic responses. </p>
<p>Patients with a recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or unstable heart disease were excluded from clinical studies during the product’s premarket testing. However, the electrocardiograms of 774 patients who received sertraline in double-blind trials were evaluated and the data indicate that sertraline is not associated with the development of significant ECG abnormalities. </p>
<p>Sertraline administered in a flexible dose range of 50 to 200 mg/day (mean dose of 89 mg/day) was evaluated in a post-marketing, placebo-controlled trial of 372 randomized subjects with a DSM-IV diagnosis of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and recent history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> requiring hospitalization. Exclusions from this trial included, among others, patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>, need for cardiac surgery, history of CABG within 3 months of index event, severe or symptomatic <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, non-atherosclerotic cause of angina, clinically significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine &gt; 2.5 mg/dl), and clinically significant hepatic dysfunction. Sertraline hydrochloride treatment initiated during the acute phase of recovery (within 30 days post-MI or post-hospitalization for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>) was indistinguishable from placebo in this study on the following week 16 treatment endpoints:  left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span>, total cardiovascular events (angina, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, CHF, MI, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and changes in BP), and major cardiovascular events involving <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or requiring hospitalization (for MI, CHF, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or angina). </p>
<p>Sertraline hydrochloride is extensively metabolized by the liver. In patients with chronic mild liver impairment, sertraline clearance was reduced, resulting in increased AUC, C<span class="Sub">max </span>and elimination half-life. The effects of sertraline in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied. The use of sertraline in patients with liver disease must be approached with caution. If sertraline is administered to patients with liver impairment, a lower or less frequent dose should be used (see <a href="#LINK_d9cd2345-271b-15b0-de40-0c30c1db0782">CLINICAL PHARMACOLOGY </a> and <a href="#LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e">DOSAGE AND ADMINISTRATION</a>). </p>
<p>Since sertraline is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. A clinical study comparing sertraline pharmacokinetics in healthy volunteers to that in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> ranging from mild to severe (requiring dialysis) indicated that the pharmacokinetics and protein binding are unaffected by <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Based on the pharmacokinetic results, there is no need for dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#LINK_d9cd2345-271b-15b0-de40-0c30c1db0782">CLINICAL PHARMACOLOGY</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_83c0bd6e-100f-b987-524b-64ac692a3db6"></a><a name="section-6.9"></a><p></p>
<h2>Interference with Cognitive and Motor Performance</h2>
<p class="First">In controlled studies, sertraline did not cause sedation and did not interfere with psychomotor performance. (See <span class="Bold"><a href="#LINK_028ac8bd-3815-2b83-6784-3370ea156d48">Information for Patients</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f0649c32-691e-2a00-05a0-0bab864238f8"></a><a name="section-6.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> may occur as a result of treatment with SSRIs and SNRIs, including sertraline hydrochloride. In many cases, this <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> appears to be the result of the syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span> (<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span>). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk (see <a href="#LINK_c96a5332-7370-3861-fc0d-f29b907a544e">GERIATRIC USE</a> ). Discontinuation of sertraline hydrochloride should be considered in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> and appropriate medical intervention should be instituted. </p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> include <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, difficulty concentrating, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">unsteadiness</span>, which may lead to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>. Signs and symptoms associated with more severe and/or acute cases have included <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f0d97ab7-a1e0-beab-5bb4-dcc708e120b0"></a><a name="section-6.11"></a><p></p>
<h2>Platelet Function</h2>
<p class="First">There have been rare reports of altered platelet function and/or abnormal results from laboratory studies in patients taking sertraline hydrochloride. While there have been reports of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> in several patients taking sertraline, it is unclear whether sertraline hydrochloride had a causative role.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_028ac8bd-3815-2b83-6784-3370ea156d48"></a><a name="section-6.12"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with sertraline hydrochloride and should counsel them in its appropriate use. A patient Medication Guide about 'Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illness, and Suicidal Thoughts or Actions' is available for sertraline hydrochloride. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.</p>
<p>Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking sertraline hydrochloride. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6aa861c7-cf93-b0a0-e98a-3402669a10fb"></a><a name="section-6.13"></a><p></p>
<h2>Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<p class="First">Patients, their families, and their caregivers should be encouraged to be alert to the emergence of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressiveness</span>, impulsivity, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> (<span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">psychomotor restlessness</span>), <span class="product-label-link" type="condition" conceptid="4333678" conceptname="Hypomania">hypomania</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, other unusual changes in behavior, worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt.  Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication. </p>
<p>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the concomitant use of SNRIs and SSRIs, including sertraline hydrochloride, and triptans, tramadol, or other serotonergic agents.</p>
<p>Patients should be told that although sertraline has not been shown to impair the ability of normal subjects to perform tasks requiring complex motor and mental skills in laboratory experiments, drugs that act upon the central nervous system may affect some individuals adversely. Therefore, patients should be told that until they learn how they respond to sertraline hydrochloride they should be careful doing activities when they need to be alert, such as driving a car or operating machinery. </p>
<p>Patients should be cautioned about the concomitant use of sertraline and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since the combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
<p>Patients should be told that although sertraline hydrochloride has not been shown in experiments with normal subjects to increase the mental and motor skill impairments caused by alcohol, the concomitant use of sertraline hydrochloride and alcohol is not advised.</p>
<p>Patients should be told that while no adverse interaction of sertraline hydrochloride  with over-the-counter (OTC) drug products is known to occur, the potential for interaction exists. Thus, the use of any OTC product should be initiated cautiously according to the directions of use given for the OTC product. </p>
<p>Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. </p>
<p>Patients should be advised to notify their physician if they are breast feeding an infant. </p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_fb67093b-53f3-bf61-a999-684bb820175b"></a><a name="section-6.14"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_733298d7-7337-b2db-2e46-398fbdbcc11b"></a><a name="section-6.15"></a><p></p>
<h2>Drug Interactions</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c3ee9d0c-0bcb-e4f2-3e4c-8ea3fb3ec433"></a><a name="section-6.16"></a><p></p>
<h2>Potential Effects of Coadministration of Drugs Highly Bound to Plasma Proteins</h2>
<p class="First">Because sertraline is tightly bound to plasma protein, the administration of sertraline hydrochloride to a patient taking another drug which is tightly bound to protein (e.g., warfarin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect. Conversely, adverse effects may result from displacement of protein bound sertraline by other tightly bound drugs. </p>
<p>In a study comparing <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time AUC (0-120 hr) following dosing with warfarin (0.75 mg/kg) before and after 21 days of dosing with either sertraline (50-200 mg/day) or placebo, there was a mean increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time of 8% relative to baseline for sertraline compared to a 1% decrease for placebo (p&lt;0.02). The normalization of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time for the sertraline hydrochloride group was delayed compared to the placebo group. The clinical significance of this change is unknown. Accordingly, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be carefully monitored when sertraline therapy is initiated or stopped. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9bcd344f-b3fc-a7ae-30f2-341d72100ce4"></a><a name="section-6.17"></a><p></p>
<h2>Cimetidine</h2>
<p class="First">In a study assessing disposition of sertraline hydrochloride (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline hydrochloride mean AUC (50%), C<span class="Sub">max</span> (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c9288dea-4b02-402b-cdbd-be42f7c9f7bb"></a><a name="section-6.18"></a><p></p>
<h2>CNS Active Drugs</h2>
<p class="First">In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline hydrochloride group compared to a 19% decrease relative to baseline for the placebo group (p&lt;0.03). There was a 23% increase in T<span class="Sub">max</span> for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p&lt;0.03). The clinical significance of these changes is unknown. </p>
<p>In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline hydrochloride did not significantly alter steady-state lithium levels or the renal clearance of lithium. </p>
<p>Nonetheless, at this time, it is recommended that plasma lithium levels be monitored following initiation of sertraline hydrochloride therapy with appropriate adjustments to the lithium dose. </p>
<p>In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and C<span class="Sub">max</span> of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline hydrochloride and pimozide should be contraindicated (see <a href="#LINK_a85ba30a-ba76-4070-d76f-c5209dc256d8">CONTRAINDICATIONS</a> ). </p>
<p>Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonethless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline hydrochloride therapy with appropriate adjustments to the phenytoin dose, practiculary in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.                                                                                                                                                                                               <br><br>The effect of sertraline on valproate levels has not been evaluated in clinical trials. In the absence of such data, it is recommended that plasma valproate levels be monitored following initiation of sertraline therapy with appropriate adjustments to the valproate dose.  </p>
<p>The risk of using sertraline in combination with other CNS active drugs has not been systematically evaluated. Consequently, caution is advised if the concomitant administration of sertraline and such drugs is required. </p>
<p>There is limited controlled experience regarding the optimal timing of switching from other drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and <span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">premenstrual dysphoric disorder</span> to sertraline. Care and prudent medical judgment should be exercised when switching, particularly from long-acting agents. The duration of an appropriate washout period which should intervene before switching from one selective serotonin reuptake inhibitor (SSRI) to another has not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f1e9548f-2b1f-a795-77ce-98ef38b2e1cb"></a><a name="section-6.19"></a><p></p>
<h2>Monoamine Oxidase Inhibitors</h2>
<p class="First">See <a href="#LINK_a85ba30a-ba76-4070-d76f-c5209dc256d8">CONTRAINDICATIONS</a> and <a href="#LINK_7bbfca91-65da-50bd-aeb2-941879634f98">WARNINGS</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2624f96c-0e98-2828-c564-302f25c13a06"></a><a name="section-6.20"></a><p></p>
<h2>Drugs Metabolized by P450 3A4</h2>
<p class="First">In three separate <span class="Italics">in vivo</span> interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and C<span class="Sub">max</span> were reduced by about 35%). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_46063283-b0f3-9e11-cd76-310d789ea73b"></a><a name="section-6.21"></a><p></p>
<h2>Drugs Metabolized by P450 2D6</h2>
<p class="First">Many drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of co-administered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the co-administered drug. There is variability among the drugs effective in the treatment of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline hydrochloride may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline hydrochloride is withdrawn from co-therapy, an increased dose of the co-administered drug may be required (see <a href="#LINK_bd84f1cd-0e6c-e8aa-09a2-9f213386b423">Tricyclic Antidepressant Drugs Effective in the Treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> under PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_36d3dffb-79e2-3cda-9481-61d2a8385968"></a><a name="section-6.22"></a><p></p>
<h2>Serotonergic Drugs</h2>
<p class="First">Based on the mechanism of action of SNRIs and SSRIs, including sertraline hydrochloride, and the potential for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, caution is advised when SNRIs and SSRIs, including sertraline hydrochloride, are coadministered with other drugs that may affect the serotonergic neutrotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John’s Wort (see <a href="#LINK_29628d2b-27c5-4527-ec38-23e7d0e08d09">WARNINGS-<span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a>). The concomitant use of sertraline hydrochloride with other SSRIs, SNRIs or tryptophan is not recommended (see <a href="#LINK_733298d7-7337-b2db-2e46-398fbdbcc11b">PRECAUTIONS – Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f19a436-2db0-4256-a783-0c5492129a65"></a><a name="section-6.23"></a><p></p>
<h2>Triptans</h2>
<p class="First">There have been rare post marketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of an SNRI or an SSRI and a triptan. If concomitant treatment of SNRIs and SSRIs, including sertraline hydrochloride, with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see <a href="#LINK_29628d2b-27c5-4527-ec38-23e7d0e08d09">WARNINGS – <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4bde68a6-21ec-50cb-920d-23fdda039a7d"></a><a name="section-6.24"></a><p></p>
<h2>Sumatriptan</h2>
<p class="First">There have been rare post marketing reports describing patients with <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, and <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bd84f1cd-0e6c-e8aa-09a2-9f213386b423"></a><a name="section-6.25"></a><p></p>
<h2>Tricyclic Antidepressant Drugs Effective in the Treatment of Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> (TCAs)</h2>
<p class="First">The extent to which SSRI–TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with sertraline, because sertraline may inhibit TCA metabolism. Plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced, if a TCA is co-administered with sertraline (see <a href="#LINK_46063283-b0f3-9e11-cd76-310d789ea73b">Drugs Metabolized by P450 2D6 under PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_977a6f7b-cfb9-a5bf-a8ef-9b45baa3fbc8"></a><a name="section-6.26"></a><p></p>
<h2>Hypoglycemic Drugs</h2>
<p class="First">In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ad5056f8-ef57-a5be-f1bf-17d1ec8f43f5"></a><a name="section-6.27"></a><p></p>
<h2>Atenolol</h2>
<p class="First">Sertraline (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_347ac76d-10cc-22f7-2663-c7c75b9eded2"></a><a name="section-6.28"></a><p></p>
<h2>Digoxin</h2>
<p class="First">In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a81a0e2c-51be-6bd2-e98c-3fbaaecb7b48"></a><a name="section-6.29"></a><p></p>
<h2>Microsomal Enzyme Induction</h2>
<p class="First">Preclinical studies have shown sertraline to induce hepatic microsomal enzymes. In clinical studies, sertraline was shown to induce hepatic enzymes minimally as determined by a small (5%) but statistically significant decrease in antipyrine half-life following administration of 200 mg/day for 21 days. This small change in antipyrine half-life reflects a clinically insignificant change in hepatic metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_430e8440-7e6d-7f01-8aaf-a87a58e91498"></a><a name="section-6.30"></a><p></p>
<h2>Drugs That Interfere With Hemostasis (Non-selective NSAIDs, Aspirin, Warfarin, etc.)</h2>
<p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of  the case-control and cohort design that have demonstrated an association between the use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Altered anticoagulant effects, including increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, have been reported when SSRIs or SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when sertraline hydrochloride is initiated or discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_efd322bb-3483-d9c8-30b6-43c8eae5275d"></a><a name="section-6.31"></a><p></p>
<h2>Electroconvulsive Therapy</h2>
<p class="First">There are no clinical studies establishing the risks or benefits of the combined use of electroconvulsive therapy (ECT) and sertraline hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2fc65e69-1bbd-3b83-79fd-0a46e9b126f8"></a><a name="section-6.32"></a><p></p>
<h2>Alcohol</h2>
<p class="First">Although sertraline did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of sertraline and alcohol is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_d826eb88-6873-a3df-ee9d-acb65ee8898f"></a><a name="section-6.33"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">Lifetime carcinogenicity studies were carried out in CD-1 mice and Long-Evans rats at doses up to 40 mg/kg/day. These doses correspond to 1 times (mice) and 2 times (rats) the maximum recommended human dose (MRHD) on a mg/m<span class="Sup">2</span> basis. There was a dose-related increase of liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in male mice receiving sertraline at 10-40 mg/kg (0.25-1.0 times the MRHD on a mg/m<span class="Sup">2</span> basis). No increase was seen in female mice or in rats of either sex receiving the same treatments, nor was there an increase in hepatocellular carcinomas. Liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> have a variable rate of spontaneous occurrence in the CD-1 mouse and are of unknown significance to humans. There was an increase in follicular <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the thyroid in female rats receiving sertraline at 40 mg/kg (2 times the MRHD on a mg/m<span class="Sup">2 </span>basis); this was not accompanied by <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span>. While there was an increase in uterine adenocarcinomas in rats receiving sertraline at 10-40 mg/kg (0.5-2.0 times the MRHD on a mg/m<span class="Sup">2 </span>basis) compared to placebo controls, this effect was not clearly drug related.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a377df35-188b-dc91-afc0-96950a519769"></a><a name="section-6.34"></a><p></p>
<h2>Mutagenesis</h2>
<p class="First">Sertraline had no genotoxic effects, with or without metabolic activation, based on the following assays: bacterial mutation assay; mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutation assay; and tests for cytogenetic aberrations <span class="Italics">in vivo</span> in mouse bone marrow and <span class="Italics">in vitro</span> in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_90f57a60-4aee-d1dc-926a-3c797f900880"></a><a name="section-6.35"></a><p></p>
<h2>Impairment of Fertility</h2>
<p class="First">A decrease in fertility was seen in one of two rat studies at a dose of 80 mg/kg (4 times the maximum recommended human dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_d2b3cd80-5760-9c9b-6836-cef7d22edb95"></a><a name="section-6.36"></a><p></p>
<h2>Pregnancy–Pregnancy Category C</h2>
<p class="First">Reproduction studies have been performed in rats and rabbits at doses up to 80 mg/kg/day and 40 mg/kg/day, respectively. These doses correspond to approximately 4 times the maximum recommended human dose (MRHD) on a mg/m<span class="Sup">2</span> basis. There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at any dose level. When pregnant rats and rabbits were given sertraline during the period of organogenesis, delayed ossification was observed in fetuses at doses of 10 mg/kg (0.5 times the MRHD on a mg/m<span class="Sup">2</span> basis) in rats and 40 mg/kg (4 times the MRHD on a mg/m<span class="Sup">2</span> basis) in rabbits.</p>
<p>When female rats received sertraline during the last third of gestation and throughout lactation, there was an increase in the number of stillborn pups and in the number of pups dying during the first 4 days after birth. Pup body weights were also decreased during the first four days after birth. These effects occurred at a dose of 20 mg/kg (1 times the MRHD on a mg/m<span class="Sup">2</span> basis). The no effect dose for rat pup mortality was 10 mg/kg (0.5 times the MRHD on a mg/m<span class="Sup">2</span> basis). The decrease in pup survival was shown to be due to <span class="Italics">in utero</span> exposure to sertraline. The clinical significance of these effects is unknown. There are no adequate and well-controlled studies in pregnant women. Sertraline hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_33c7d2c3-25da-2405-7ef3-28e74162ccc2"></a><a name="section-6.37"></a><p></p>
<h2>Pregnancy-Nonteratogenic Effects</h2>
<p class="First">Neonates exposed to sertraline and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.  These findings are based on postmarketing reports. Such complications can arise immediately upon delivery. Reported clinical findings have included <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temperature instability, feeding difficulty, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and constant <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> (see <a href="#LINK_7bbfca91-65da-50bd-aeb2-941879634f98">WARNINGS</a>).  </p>
<p>Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> of the newborn (PPHN). (PPHN) occurs in 1-2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20<span class="Sup">th</span> week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative evidence regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that has investigated the potential risk. The study did not include enough cases with exposure to individual SSRIs to determine if all SSRIs posed similar levels of PPHN risk.  </p>
<p>When treating a pregnant woman with sertraline during the third trimester, the physician should carefully consider the potential risks and benefits of treatment (see <a href="#LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e">DOSAGE AND ADMINISTRATION</a>). Physicians should note that in a prospective longitudinal study of 201 women with a history of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> who were euthyrnic in the context of antidepressant therapy at the beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of <span class="product-label-link" type="condition" conceptid="4114950" conceptname="Endogenous depression">major depression</span> than women who continued antidepressant medication. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_0b8905a1-ca26-5e4a-fdeb-627658d2f096"></a><a name="section-6.38"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">The effect of sertraline on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_194ec4e6-49d7-87fb-fbd3-a1c532ffcfad"></a><a name="section-6.39"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether, and if so in what amount, sertraline or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sertraline is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_939d50b1-c90c-d113-98b2-167fbee20dba"></a><a name="section-6.40"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> have not been established (see <a href="#LINK_9bb26bb2-6269-56e8-e9d9-9d5035f7ea25">BOX WARNING </a>and <a href="#LINK_7bbfca91-65da-50bd-aeb2-941879634f98">WARNINGS</a>, <a href="#LINK_cdf73175-d627-8046-9062-cbf9b6840603">Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a>). Two placebo controlled trials (n=373) in pediatric patients with MDD have been conducted with sertraline hydrochloride, and the data were not sufficient to support a claim for use in pediatric patients. Anyone considering the use of sertraline hydrochloride tablets in a child or adolescent must balance the potential risks with the clinical need. </p>
<p>Sertraline pharmacokinetics were evaluated in a group of 61 pediatric patients between 6 and 17 years of age and revealed similar drug exposures to those of adults when plasma concentration was adjusted for weight (see <a href="#LINK_ab8959f3-622c-a71b-6d28-1039b3a05d6d">Pharmacokinetics </a> under <a href="#LINK_ab8959f3-622c-a71b-6d28-1039b3a05d6d">CLINICAL PHARMACOLOGY</a>). </p>
<p>Approximately 600 pediatric patients between 6 and 17 years of age have received sertraline in clinical trials, both controlled and uncontrolled. The adverse event profile observed in these patients was generally similar to that observed in adult studies with sertraline hydrochloride (see <a href="#LINK_251afde8-474f-b6f8-ca69-73655f31797e">ADVERSE REACTIONS</a>). As with other SSRIs, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> have been observed in association with the use of sertraline hydrochloride. In a pooled analysis of two 10­-week, double-blind, placebo-controlled, flexible dose (50-200 mg) outpatient trials for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> (n=373), there was a difference in weight change between sertraline and placebo of roughly 1 kilogram, for both children (ages 6-11) and adolescents (ages 12-17), in both cases representing a slight <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> for sertraline compared to a slight gain for placebo. At baseline the mean weight for children was   39.0 kg for sertraline and 38.5 kg for placebo. At baseline the mean weight for adolescents was 61.4 kg for sertraline and 62.5 kg for placebo. There was a bigger difference between sertraline and placebo in the proportion of outliers for clinically important <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> in children than in adolescents. For children, about 7% had a <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> &gt; 7% of body weight compared to none of the placebo patients; for adolescents, about 2% had a <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> &gt; 7% of body weight compared to about 1% of the placebo patients. A subset of these patients who completed the randomized controlled trials (sertraline n=99, placebo n=122) were continued into a 24-week, flexible-dose, open-label, extension study. A mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of approximately 0.5 kg was seen during the first eight weeks of treatment for subjects with first exposure to sertraline during the open-label extension study, similar to the mean <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> observed among sertraline treated subjects during the first eight weeks of the randomized controlled trials. The subjects continuing in the open label study began gaining weight compared to baseline by week 12 of sertraline treatment. Those subjects who completed 34 weeks of sertraline treatment (10 weeks in a placebo controlled trial + 24 weeks open label, n=68), had <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> that was similar to that expected using data from age-adjusted peers. Regular monitoring of weight and growth is recommended if treatment of a pediatric patient with an SSRI is to be continued long term. Safety and effectiveness in pediatric patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> have not been established.</p>
<p>The risks, if any, that may be associated with sertraline hydrochloride’s use beyond 1 year in children and adolescents have not been systematically assessed. The prescriber should be mindful that the evidence relied upon to conclude that sertraline is safe for use in children and adolescents derives from clinical studies that were 10 to 52 weeks in duration and from the extrapolation of experience gained with adult patients. In particular, there are no studies that directly evaluate the effects of long-term sertraline use on the growth, development, and maturation of children and adolescents. Although there is no affirmative finding to suggest that sertraline possesses a capacity to adversely affect growth, development or maturation, the absence of such findings is not compelling evidence of the absence of the potential of sertraline to have adverse effects in chronic use (see <span class="Bold"><a href="#LINK_cdf73175-d627-8046-9062-cbf9b6840603">WARNINGS – Clinical Worsening and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_c96a5332-7370-3861-fc0d-f29b907a544e"></a><a name="section-6.41"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">U.S. geriatric clinical studies of sertraline hydrochloride in major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> included 663 sertraline-treated subjects ≥ 65 years of age, of those, 180 were ≥ 75 years of age. No overall differences in the pattern of adverse reactions were observed in the geriatric clinical trial subjects relative to those reported in younger subjects (see <a href="#LINK_251afde8-474f-b6f8-ca69-73655f31797e">ADVERSE REACTIONS</a>), and other reported experience has not identified differences in safety patterns between the elderly and younger subjects. As with all medications, greater sensitivity of some older individuals cannot be ruled out. There were 947 subjects in placebo-controlled geriatric clinical studies of sertraline hydrochloride in major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>. No overall differences in the pattern of efficacy were observed in the geriatric clinical trial subjects relative to those reported in younger subjects.</p>
<p>Other Adverse Events in Geriatric Patients. In 354 geriatric subjects treated with sertraline in placebo-controlled trials, the overall profile of adverse events was generally similar to that shown in Table 2. <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> was the only adverse event not appearing in Table 2 and reported at an incidence of at least 2% and at a rate greater than placebo in placebo-controlled trials.</p>
<p>SSRIS and SNRIs, including sertraline hydrochloride, have been associated with cases of clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in elderly patients, who may be at greater risk for this adverse event (see <a href="#LINK_f0649c32-691e-2a00-05a0-0bab864238f8">PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_251afde8-474f-b6f8-ca69-73655f31797e"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">During its premarketing assessment, multiple doses of sertraline hydrochloride were administered to over 4000 adult subjects as of February 18, 2000. The conditions and duration of exposure to sertraline hydrochloride varied greatly, and included (in overlapping categories) clinical pharmacology studies, open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies, and studies for multiple indications, including major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and PMDD. </p>
<p>Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories. </p>
<p>In the tabulations that follow, a World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the over 4000 adult individuals exposed to multiple doses of sertraline hydrochloride who experienced a treatment-emergent adverse event of the type cited on at least one occasion while receiving sertraline hydrochloride. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that events reported during therapy were not necessarily caused by it. </p>
<p>The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the side effect incidence rate in the population studied. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3295a46-0400-5e1a-2c9b-2dcdb86b6f71"></a><a name="section-7.1"></a><p></p>
<h2>Incidence in Placebo-Controlled Trials</h2>
<p class="First">Table 2 enumerates the most common treatment-emergent adverse events associated with the use of sertraline hydrochloride (incidence of at least 5% for sertraline hydrochloride and at least twice that for placebo) for the treatment of adult patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>/other* in placebo-controlled clinical trials. Most patients in major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>/other* and PMDD studies received doses of 50 to 200 mg/day. </p>
<p>Patients in the PMDD study with daily dosing throughout the menstrual cycle received doses of 50 to 150 mg/day, and in the PMDD study with dosing during the luteal phase of the menstrual cycle received doses of 50 to 100 mg/day.</p>
<p><span class="Bold">TABLE 2<br>MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS: <br></span><span class="Bold">INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS</span></p>
<table border="1" cellpadding="0" cellspacing="0">
<col width="45.9pt">
<col width="27.75pt">
<col width="25.85pt">
<col width="32.65pt">
<col width="31.5pt">
<col width="27pt">
<col width="28.15pt">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="4"><p class="First"><span class="Bold">Percentage of Patients Reporting Event </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>/Other*</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2">
<p class="First"><span class="Bold">PMDD </span></p>
<p><span class="Bold">Daily Dosing</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">PMDD Luteal Phase Dosing(<span class="Sup">2</span>)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Body System/Adverse Event </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Sertraline</span></p>
<p><span class="Bold">Hydrochloride</span></p>
<p><span class="Bold"> (N=861)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (N=853)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Sertraline</span></p>
<p><span class="Bold">Hydrochloride</span></p>
<p><span class="Bold"> (N=121)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (N=122)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Sertraline</span></p>
<p><span class="Bold">Hydrochloride</span></p>
<p><span class="Bold">(N=136)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (N=127)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation Failure</span><span class="Sup">(1)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">N/A</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">N/A</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">N/A</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">N/A</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Mouth Dry</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating Increased</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Center. &amp; Periph. Nerv. System Disorders </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">General </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose Stools</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Psychiatric Disorders </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido Decreased</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">(1)</span>Primarily ejaculatory delay. Denominator used was for male patients only (N=271 sertraline hydrochloride major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>/other*; N=271 placebo major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>/other*; No male patients in PMDD studies.<br>*Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and other premarketing controlled trials. </p>
<p><span class="Sup">(2)</span>The luteal phase and daily dosing PMDD trials were not designed for making direct comparisons between the two dosing regimens. Therefore, a comparison between the two dosing regimens of the PMDD trials of incidence rates shown in Table 2 should be avoided. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bf02e05c-1416-514a-7a69-0fc8ced3c719"></a><a name="section-7.2"></a><p></p>
<h2>Associated with Discontinuation in Placebo-Controlled Clinical Trials</h2>
<p class="First">Table 3 lists the adverse events associated with discontinuation of sertraline treatment (incidence at least twice that for placebo and at least 1% for sertraline in clinical trials) in major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>/other*and PMDD.  </p>
<p><span class="Bold">TABLE 3<br></span><span class="Bold">MOST COMMON ADVERSE EVENTS ASSOCIATED WITH DISCONTINUATION<br></span><span class="Bold">IN PLACEBO-CONTROLLED CLINICAL TRIALS</span></p>
<table border="1" cellpadding="0" cellspacing="0">
<col width="55.45pt">
<col width="0.75in">
<col width="45pt">
<col width="63pt">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Adverse Event </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span>/ Other* (N=861) </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">PMDD Daily Dosing (N=121) </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">PMDD Luteal Phase Dosing (N=136) </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/ <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose Stools</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation Failure</span>(1) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N/A </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N/A </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2% </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">– </p></td>
</tr>
</tbody>
</table>
<span class="Sup">(1)</span>Primarily ejaculatory delay. Denominator used was for male patients only <br>   (N=271 major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>/other*; No male patients in PMDD studies.<br>*Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> and other premarketing controlled trials.              
             </div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_34882782-87ea-c04a-309a-3c185af56cc3"></a><a name="section-7.3"></a><p></p>
<h2>Male and Female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">Sexual Dysfunction</span> with SSRIs</h2>
<p class="First">Although changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment.  In particular, some evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can cause such untoward sexual experiences.  Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them.  Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling, are likely to underestimate their actual incidence. </p>
<p>Table 4 below displays the incidence of sexual side effects reported by at least 2% of patients taking sertraline hydrochloride in placebo-controlled trials.</p>
<p><span class="Bold">TABLE 4</span></p>
<table border="0" cellpadding="0" cellspacing="0">
<col width="94.5pt">
<col width="51.75pt">
<col width="65.25pt">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Sertraline </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">Ejaculation failure</span>*(primarily delayed ejaculation)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Decreased libido**</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1%</p></td>
</tr>
</tbody>
</table>
<p>*Denominator used was for male patients only (N=1118 sertraline; N=926 placebo) <br>**Denominator used was for male and female patients (N=2799 sertraline hydrochloride; N=2394 placebo)</p>
<p>There are no adequate and well-controlled studies examining <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> with sertraline treatment.</p>
<p><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> has been reported with all SSRIs.</p>
<p>While it is difficult to know the precise risk of <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span> associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_89863952-f822-69c2-882d-3477a4869857"></a><a name="section-7.4"></a><p></p>
<h2>Other Adverse Events in Pediatric Patients</h2>
<p class="First">In over 600 pediatric patients treated with sertraline, the overall profile of adverse events was generally similar to that seen in adult studies. However, the following adverse events, from controlled trials, not appearing in Tables 2 and 3, were reported at an incidence of at least 2% and occurred at a rate of at least twice the placebo rate (N=281 patients treated with sertraline): <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> and <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fdcf4ebf-e1a4-9dcc-d868-fb3de2c980de"></a><a name="section-7.5"></a><p></p>
<h2>Other Events Observed During the Premarketing Evaluation of Sertraline Hydrochloride</h2>
<p class="First">Following is a list of treatment-emergent adverse events reported during premarketing assessment of sertraline hydrochloride in clinical trials (over 4000 adult subjects) except those already listed in the previous tables or elsewhere in labeling. </p>
<p>In the tabulations that follow, a World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the over 4000 adult individuals exposed to multiple doses of sertraline hydrochloride who experienced an event of the type cited on at least one occasion while receiving sertraline hydrochloride. All events are included except those already listed in the previous tables or elsewhere in labeling and those reported in terms so general as to be uninformative and those for which a causal relationship to sertraline hydrochloride treatment seemed remote. It is important to emphasize that although the events reported occurred during treatment with sertraline, they were not necessarily caused by it. </p>
<p>Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients. Events of major clinical importance are also described in the <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a> section.</p>
<p><span class="Bold">Autonomic Nervous System Disorders–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, increased saliva, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, vasodilation.</p>
<p><span class="Bold">Body as a Whole–General Disorders–</span><span class="Italics">Rare: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
<p><span class="Bold">Cardiovascular–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, postural <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">periorbital edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>; <span class="Italics">Rare:</span> precordial <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">substernal chest pain</span>, aggravated <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>.</p>
<p><span class="Bold">Central and Peripheral Nervous System Disorders–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, abnormal coordination, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="4181630" conceptname="Choreoathetosis">choreoathetosis</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>.</p>
<p><span class="Bold">Disorders of Skin and Appendages–</span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>; <span class="Italics">Rare:</span> follicular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruption</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustular rash</span>.</p>
<p><span class="Bold">Endocrine Disorders–</span><span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
<p><span class="Bold">Gastrointestinal Disorders–</span><span class="Italics">Frequent:</span> appetite increased; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries aggravated</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, tenesmus, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, rectum <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, hemorrhagic <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>, <span class="product-label-link" type="condition" conceptid="4278836" conceptname="Ulcer on tongue">tongue ulceration</span>.</p>
<p><span class="Bold">General–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>; <span class="Italics">Rare:</span> face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>.</p>
<p><span class="Bold">Hearing and Vestibular Disorders–</span><span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="78771" conceptname="Labyrinthine dysfunction">labyrinthine disorder</span>.</p>
<p><span class="Bold">Hematopoietic and Lymphatic–</span><span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, anterior chamber <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span>.</p>
<p><span class="Bold">Liver and Biliary System Disorders–</span><span class="Italics">Rare:</span> abnormal hepatic function.</p>
<p><span class="Bold">Metabolic and Nutritional Disorders–</span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> reaction.</p>
<p><span class="Bold">Musculoskeletal System Disorders–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</p>
<p><span class="Bold">Psychiatric Disorders–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, other male <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, other female <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">paroniria</span>, teeth-grinding, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>; <span class="Italics">Rare:</span> withdrawal syndrome, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> ideation, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, <span class="product-label-link" type="condition" conceptid="377535" conceptname="Sleep walking disorder">somnambulism</span>, <span class="product-label-link" type="condition" conceptid="4238753" conceptname="Optical illusion">illusion</span>.</p>
<p><span class="Bold">Reproductive–</span><span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>; <span class="Italics">Rare:</span> female <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="436466" conceptname="Balanoposthitis">balanoposthitis</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="201078" conceptname="Atrophic vaginitis">atrophic vaginitis</span>, acute female <span class="product-label-link" type="condition" conceptid="4163232" conceptname="Mastitis">mastitis</span>.</p>
<p><span class="Bold">Respiratory System Disorders–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">bradypnea</span>, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>. </p>
<p><span class="Bold">Special Senses–</span><span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, abnormal accommodation; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, abnormal <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>.</p>
<p><span class="Bold">Urinary System Disorders–</span><span class="Italics">Infrequent:</span> micturition frequency, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>; <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span>, strangury.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_eb462ecf-dc59-ac19-32ef-970f0492994c"></a><a name="section-7.6"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">In man, asymptomatic elevations in serum transaminases (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> [or AST] and SGPT [or ALT]) have been reported infrequently (approximately 0.8%) in association with sertraline hydrochloride administration. These hepatic enzyme elevations usually occurred within the first 1 to 9 weeks of drug treatment and promptly diminished upon drug discontinuation. </p>
<p>Sertraline hydrochloride therapy was associated with small mean increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (approximately 3%) and triglycerides (approximately 5%), and a small mean decrease in serum uric acid (approximately 7%) of no apparent clinical importance. </p>
<p>The safety profile observed with sertraline treatment in patients with major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, and PMDD is similar. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e14eb6c7-77c7-4b2f-749a-66bd4023c1df"></a><a name="section-7.7"></a><p></p>
<h2>Other Events Observed During the Post marketing Evaluation of Sertraline Hydrochloride</h2>
<p class="First">Reports of adverse events temporally associated with sertraline hydrochloride that have been received since market introduction, that are not listed above and that may have no causal relationship with the drug, include the following: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, increased coagulation times, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span>, QT-interval prolongation, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (including <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>-type <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>), <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, lupus-like syndrome, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, which potentially can be fatal, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and other severe cutaneous disorders, rare reports of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and liver events—clinical features (which in the majority of cases appeared to be reversible with discontinuation of sertraline hydrochloride) occurring in one or more patients include: elevated enzymes, increased bilirubin, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_e344c706-a25c-1bec-a9a7-823743b67b50"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="LINK_e813f26f-cb54-4ae4-7903-1af79fa1c173"></a><a name="section-8.1"></a><p></p>
<h2>Controlled Substance Class</h2>
<p class="First">Sertraline hydrochloride is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="LINK_fcacde42-cba5-6a04-16aa-c1c909921da3"></a><a name="section-8.2"></a><p></p>
<h2>Physical and Psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">In a placebo-controlled, double-blind, randomized study of the comparative abuse liability of sertraline hydrochloride, alprazolam, and d-amphetamine in humans, sertraline hydrochloride did not produce the positive subjective effects indicative of abuse potential, such as <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> or drug liking, that were observed with the other two drugs. Premarketing clinical experience with sertraline hydrochloride did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior. In animal studies sertraline hydrochloride does not demonstrate stimulant or barbiturate-like (depressant) abuse potential. As with any CNS active drug, however, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of sertraline hydrochloride misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_97d82178-4a18-0650-ff49-bf5ad9e454f3"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a1562fa7-4b09-6214-451a-41c14dbbbc5f"></a><a name="section-9.1"></a><p></p>
<h2>Human Experience</h2>
<p class="First">Of 1,027 cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> involving sertraline hydrochloride worldwide, alone or with other drugs, there were 72 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (circa 1999). Among 634 <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> in which sertraline hydrochloride was the only drug ingested, 8 resulted in fatal outcome, 75 completely recovered, and 27 patients experienced sequelae after overdosage to include <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>. The remaining 524 cases had an unknown outcome. The most common signs and symptoms associated with non-fatal sertraline hydrochloride overdosage were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. </p>
<p>The largest known ingestion was 13.5 grams in a patient who took sertraline hydrochloride alone and subsequently recovered. However, another patient who took   2.5 grams of sertraline hydrochloride alone experienced a fatal outcome. </p>
<p>Other important adverse events reported with sertraline hydrochloride <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (single or multiple drugs) include <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">bundle branch block</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, QT-interval prolongation, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_034fc571-7790-276c-4b14-bfdf46cb1e1c"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> Management</h2>
<p class="First">Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. </p>
<p>Ensure an adequate airway, oxygenation and ventilation.  Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. </p>
<p>Activated charcoal should be administered. Due to large volume of distribution of this drug, forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for sertraline are known. </p>
<p>In managing overdosage, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control center on the treatment of any <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Telephone numbers for certified poison control centers are listed in the <span class="Italics">Physicians’ Desk Reference</span>(PDR).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_a4a5c4a3-1ba5-942c-75ba-543717fd2c5e"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d0bc0bc8-d12d-96d7-8f1c-c461a1dc4aae"></a><a name="section-10.1"></a><p></p>
<h2>Initial Treatment</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7f3d0833-6dfe-329a-5886-6ee416871c7d"></a><a name="section-10.2"></a><p></p>
<h2>Dosage for Adults</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ad26fb81-d904-a4d0-2a6f-926783f1df58"></a><a name="section-10.3"></a><p></p>
<h2>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span> and Obsessive-Compulsive Disorder</h2>
<p class="First">Sertraline treatment should be administered at a dose of 50 mg once daily. </p>
<p>While a relationship between dose and effect has not been established for major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span>, patients were dosed in a range of 50-200 mg/day in the clinical trials demonstrating the effectiveness of sertraline hydrochloride for the treatment of this indication. Consequently, a dose of 50 mg, administered once daily, is recommended as the initial therapeutic dose. Patients not responding to a 50 mg dose may benefit from dose increases up to a maximum of 200 mg/day. Given the 24 hour elimination half-life of sertraline hydrochloride, dose changes should not occur at intervals of less than 1 week.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b3cf4cf3-5d58-792c-d10f-65bdb50c4dd2"></a><a name="section-10.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">Premenstrual Dysphoric Disorder</span></h2>
<p class="First">Sertraline treatment should be initiated with a dose of  50 mg/day, either daily throughout the menstrual cycle or limited to the luteal phase of the menstrual cycle, depending on physician assessment. </p>
<p>While a relationship between dose and effect has not been established for PMDD, patients were dosed in the range of 50-150 mg/day with dose increases at the onset of each new menstrual cycle (see <a href="#LINK_5fce1524-65a4-3b54-1903-adb6dc8f7736">Clinical Trials under CLINICAL PHARMACOLOGY</a>).  Patients not responding to a 50 mg/day dose may benefit from dose increases (at 50 mg increments/menstrual cycle) up to 150 mg/day when dosing daily throughout the menstrual cycle, or 100 mg/day when dosing </p>
<p>during the luteal phase of the menstrual cycle.  If a 100 mg/day dose has been established with luteal phase dosing, a 50 mg/day titration step for three days should be utilized at the beginning of each luteal phase dosing period.</p>
<p>Sertraline should be administered once daily, either in the morning or evening.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4f3ee87f-c252-cfbb-cb38-bfaa48bb9cfe"></a><a name="section-10.5"></a><p></p>
<h2>Maintenance/Continuation/Extended Treatment</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_49df81b4-dd9a-0193-679a-fdfbad237543"></a><a name="section-10.6"></a><p></p>
<h2>Major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depressive Disorder</span></h2>
<p class="First">It is generally agreed that acute episodes of major <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive disorder</span> require several months or longer of sustained pharmacologic therapy beyond response to the acute episode.  Systematic evaluation of sertraline has demonstrated that its antidepressant efficacy is maintained for periods of up to 44 weeks following 8 weeks of initial treatment at a dose of 50-200 mg/day (mean dose of 70 mg/day) (see <a href="#LINK_5fce1524-65a4-3b54-1903-adb6dc8f7736">Clinical Trials under CLINICAL PHARMACOLOGY</a>). It is not known whether the dose of sertraline hydrochloride needed for maintenance treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassessed to determine the need for maintenance treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_26c040cb-f2b1-77b5-e8a4-e0df66091c46"></a><a name="section-10.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4242733" conceptname="Premenstrual dysphoric disorder">Premenstrual Dysphoric Disorder</span></h2>
<p class="First">The effectiveness of sertraline in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. However, as women commonly report that symptoms worsen with age until relieved by the onset of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, it is reasonable to consider continuation of a responding patient. Dosage adjustments, which may include changes between dosage regimens (e.g., daily throughout the menstrual cycle versus during the luteal phase of the menstrual cycle), may be needed to maintain the patient on the lowest effective dosage and patients should be periodically reassessed to determine the need for continued treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_65fd2252-07c3-0367-b43b-9313e39a0fe9"></a><a name="section-10.8"></a><p></p>
<h2>Switching Patients to or from a Monoamine Oxidase Inhibitor</h2>
<p class="First">At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with sertraline hydrochloride. In addition, at least 14 days should be allowed after stopping sertraline before starting an MAOI (see <a href="#LINK_a85ba30a-ba76-4070-d76f-c5209dc256d8">CONTRAINDICATIONS</a> and <a href="#LINK_7bbfca91-65da-50bd-aeb2-941879634f98">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_21eea0fd-1e2a-fc5f-2270-f30e3358c44f"></a><a name="section-10.9"></a><p></p>
<h2>Special Populations</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_798bfe79-7a66-f29a-ac38-e825869a0933"></a><a name="section-10.10"></a><p></p>
<h2>Dosage for Hepatically Impaired Patients</h2>
<p class="First">The use of sertraline in patients with liver disease should be approached with caution. The effects of sertraline in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been studied. If sertraline is administered to patients with liver impairment, a lower or less frequent dose should be used (see <a href="#LINK_d9cd2345-271b-15b0-de40-0c30c1db0782">CLINICAL PHARMACOLOGY</a> and <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0ceccadc-c6c9-b2f2-a043-ce8e796aef0d"></a><a name="section-10.11"></a><p></p>
<h2>Treatment of Pregnant Women During the Third Trimester</h2>
<p class="First">Neonates exposed to sertraline hydrochloride and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a>).  When treating pregnant women with sertraline during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.  The physician may consider tapering sertraline in the third trimester.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b35957f5-25e8-066d-4809-69b518049085"></a><a name="section-10.12"></a><p></p>
<h2>Discontinuation of Treatment with Sertraline</h2>
<p class="First">Symptoms associated with discontinuation of sertraline and other SSRIs and SNRIs, have been reported (see <a href="#LINK_173aee5b-24a6-d818-d7c3-477a1c8096c8">PRECAUTIONS</a>). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_50b79641-13a0-0c8c-50e2-71527a620e77"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Sertraline hydrochloride tablets capsular-shaped scored tablets, containing sertraline hydrochloride equivalent to 25, 50 and 100 mg of sertraline, are packaged in bottles. </p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">53808-0587-1</td>
<td align="center">25 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">YELLOW</td>
<td align="center">31722-212</td>
</tr>
<tr>
<td align="center">53808-0579-1</td>
<td align="center">50 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">BLUE</td>
<td align="center">31722-213</td>
</tr>
<tr class="Last">
<td align="center">53808-0581-1</td>
<td align="center">100 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">Off-white</td>
<td align="center">31722-214</td>
</tr>
</tbody>
</table>
<p>Store at 20º- 25ºC (68º- 77ºF) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_480a4d97-8bd1-0a00-905f-dff1641fed0f"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Rx Only</p>
<p><span class="Bold">Camber <br></span>PISCATAWAY, NJ – USA</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br> 104-2 Hamilton Park Drive<br> Tallahassee, FL 32304<br> United States<br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="LINK_ac7f5a95-b369-0554-96e0-6772b1e164f0"></a><a name="section-13"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Antidepressant Medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other Serious Mental Illnesses, </span><span class="Bold">and Suicidal Thoughts or Actions</span></p>
<p>Read the Medication Guide that comes with you or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <br><span class="Bold">Talk to your, or your family member"s, healthcare provider about:<br></span><br>·    all risks and benefits of treatment with antidepressant medicines<br>·    all treatment choices for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other serious mental illness</p>
<p><span class="Bold">What is the most important information I should know about antidepressant medicines, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other serious mental illnesses, and suicidal thoughts or actions? </span></p>
<p><span class="Bold">1.    </span><span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults when the medicine is first started.</span></p>
<p><span class="Bold">2.     </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and other serious mental illnesses are the most </span><span class="Bold">important causes of suicidal thoughts and actions. Some people may have </span><span class="Bold">a particularly high risk of having suicidal thoughts or </span><span class="Bold">actions.</span> <br>These include people who have (or have a family history of) bipolar illness (also called <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span>-<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive illness</span>) or suicidal thoughts or actions.</p>
<p><span class="Bold">3.   How can I watch for and try to prevent suicidal thoughts and</span><span class="Bold"> actions in myself or a family </span><span class="Bold">member? <br></span><br>·    Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings. This is very important  when an antidepressant medicine is first started or when the dose is changed. <br>·    Call the health care provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.<br>·    Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed,  especially if you have concerns about symptoms.</p>
<p><span class="Bold">Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:<br></span><br>·    Thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying                                                     <br>·    Attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span><br>·    New or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span><br>·    New or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span><br>·    Feeling very <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span><br>·    <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">Panic attacks</span><br>·    Trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)<br>·    New or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span><br>·    Acting aggressive, being angry, or violent<br>·    Acting on dangerous impulses<br>·    An extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)<br>·    Other unusual changes in behavior or mood</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">     What else do I need to know about antidepressant medicines?<br></span><br>·    <span class="Bold">Never stop an antidepressant medicine without first talking to a healthcare provider. </span>Stopping an antidepressant  medicine suddenly can cause other symptoms.<br>·    <span class="Bold">Antidepressants are medicines used to treat <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and other illnesses. </span>It is important to discuss all the risks  of treating <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and also the risks of not treating it. Patients and their families or other caregivers should discuss all  treatment choices with the healthcare provider, not just the use of antidepressants.<br>·    <span class="Bold">Antidepressant medicines have other side effects. </span>Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.<br>·    <span class="Bold">Antidepressant medicines can interact with other medicines. </span>Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.<br>·    <span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children. </span>Talk to your child"s  healthcare provider for more information.</p>
<p>This medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_a1f7f90e-db34-4aff-a212-a78e53f2a1fc"></a><a name="section-14"></a><p></p>
<h1>25mg 30 Tablets Label</h1>
<div class="Figure"><img alt="25mg 30 Tablets Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=250d998f-7100-495c-81ff-10fcfd5ba61d&amp;name=Sertraline%2025mg(Camber).jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_828aadd2-c7c3-4495-915c-891329506676"></a><a name="section-15"></a><p></p>
<h1>50mg 30 Tablets Label</h1>
<div class="Figure"><img alt="50mg 30 Tablets Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=250d998f-7100-495c-81ff-10fcfd5ba61d&amp;name=Sertraline%2050mg(Camber).jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_0f25e063-f698-46fd-8da6-4ec2a674e9b1"></a><a name="section-16"></a><p></p>
<h1>100mg 30 Tablets Label</h1>
<div class="Figure"><img alt="100mg 30 Tablets Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=250d998f-7100-495c-81ff-10fcfd5ba61d&amp;name=Sertraline100mg(Camber).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SERTRALINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">sertraline hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0587(NDC:31722-212)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SERTRALINE HYDROCHLORIDE</strong> (SERTRALINE) </td>
<td class="formItem">SERTRALINE HYDROCHLORIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Elliptical) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">IG;212</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0587-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077397</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SERTRALINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">sertraline hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0579(NDC:31722-213)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SERTRALINE HYDROCHLORIDE</strong> (SERTRALINE) </td>
<td class="formItem">SERTRALINE HYDROCHLORIDE</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Elliptical) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">IG;213</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0579-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077397</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SERTRALINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">sertraline hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0581(NDC:31722-214)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SERTRALINE HYDROCHLORIDE</strong> (SERTRALINE) </td>
<td class="formItem">SERTRALINE HYDROCHLORIDE</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (Elliptical) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">IG;214</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0581-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077397</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f7280544-b20f-450a-a4f3-24c288ed2012</div>
<div>Set id: 250d998f-7100-495c-81ff-10fcfd5ba61d</div>
<div>Version: 2</div>
<div>Effective Time: 20100804</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
